- Home
- ADVM vs CGTX Comparison
ADVM vs CGTX Comparison
Compare ADVM & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- CGTX
- Stock Information
- Founded
- ADVM 2006
- CGTX 2007
- Country
- ADVM United States
- CGTX United States
- Employees
- ADVM N/A
- CGTX N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ADVM Health Care
- CGTX Health Care
- Exchange
- ADVM Nasdaq
- CGTX Nasdaq
- Market Cap
- ADVM 66.3M
- CGTX 53.4M
- IPO Year
- ADVM 2014
- CGTX 2021
- Fundamental
- Price
- ADVM $3.54
- CGTX $2.41
- Analyst Decision
- ADVM Strong Buy
- CGTX Strong Buy
- Analyst Count
- ADVM 4
- CGTX 3
- Target Price
- ADVM $19.75
- CGTX $2.83
- AVG Volume (30 Days)
- ADVM 84.4K
- CGTX 12.4M
- Earning Date
- ADVM 11-03-2025
- CGTX 08-07-2025
- Dividend Yield
- ADVM N/A
- CGTX N/A
- EPS Growth
- ADVM N/A
- CGTX N/A
- EPS
- ADVM N/A
- CGTX N/A
- Revenue
- ADVM $1,000,000.00
- CGTX N/A
- Revenue This Year
- ADVM $1,836.70
- CGTX N/A
- Revenue Next Year
- ADVM N/A
- CGTX N/A
- P/E Ratio
- ADVM N/A
- CGTX N/A
- Revenue Growth
- ADVM N/A
- CGTX N/A
- 52 Week Low
- ADVM $1.78
- CGTX $0.22
- 52 Week High
- ADVM $8.56
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- ADVM 71.73
- CGTX 61.15
- Support Level
- ADVM $2.93
- CGTX $2.26
- Resistance Level
- ADVM $3.25
- CGTX $2.67
- Average True Range (ATR)
- ADVM 0.22
- CGTX 0.40
- MACD
- ADVM 0.05
- CGTX -0.03
- Stochastic Oscillator
- ADVM 95.40
- CGTX 42.08
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.